SCHEMBL17287367

SCHEMBL17287367

CN1CCN(c2cc(C(=O)O)ccc2N)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.60
HSD17B10 Q99714 3/20 0.60
ALDH1A1 P00352 3/20 0.60
GAA P10253 5/20 0.59
MAPK1 P28482 2/20 0.59
MAPT P10636 2/20 0.59
HTT P42858 1/20 0.59
RECQL P46063 1/20 0.59
PTK2B Q14289 1/20 0.59
POLB P06746 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
NR4A1 P22736 1/20 0.54
ADRA2C P18825 1/20 0.51
CHEK1 O14757 2/20 0.47
TTR P02766 3/20 0.44
WDR5 P61964 1/20 0.43
LMNA P02545 1/20 0.43
NPC1 O15118 1/20 0.43
RAD52 P43351 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28056217 0.88 ALDH1A1 (0.78) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL15776926 0.88 KDM4E (0.78) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL23292230 0.84 GAA (0.77) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL22895657 0.84 KDM4E (0.60) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL17287387 0.81 KDM4E (0.53) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL22895541 0.81 LGMN (0.59) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL12752917 0.79 HSD17B10 (0.57) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL5827458 0.79 HTR1D (0.55) MAPK1HTTPOLBLMNANPC1
SCHEMBL28291873 0.78 KDM4E (0.53) KDM4EHSD17B10ALDH1A1GAAMAPK1
SCHEMBL2430511 0.78 KDM4E (0.56) KDM4EHSD17B10ALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11390618-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2022-07-19 US disclosed
US-11358958-B2 2022-06-14 US disclosed
US-11358958-B2 2022-06-14 US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 US disclosed
EP-3813819-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-05-05 EP disclosed
CN-112638373-A Cyclin-dependent kinase inhibitors 金耐特生物制药公司 2021-04-09 CN disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 US disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 US disclosed
US-10233165-B2 Cyclopropylamine compounds as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-03-19 US disclosed
EP-3148974-B1 CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2018-09-26 EP disclosed
US-20170190680-A1 CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-07-06 US disclosed
EP-3148974-A1 CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-04-05 EP disclosed
WO-2015181380-A1 CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2015-12-03 WO disclosed
EP-2949648-A1 Cyclopropylamine derivatives as histone demethylase inhibitors IEO - Istituto Europeo di Oncologia Srl (IT) 2015-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358958-B2 CDK2, CDK1, CDK6 KDM4E 1178/4885HSD17B10 2396/4885ALDH1A1 3425/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 KDM4E 1278/4885HSD17B10 2436/4885ALDH1A1 3722/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 KDM4E 1278/4885HSD17B10 2436/4885ALDH1A1 3722/4885
US-10233165-B2 Cyclopropylamine compounds as histone demethylase inhibitors KDM1B, PHF2, KDM6B KDM4E 14/4885HSD17B10 875/4885ALDH1A1 533/4885
US-11390618-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 KDM4E 1278/4885HSD17B10 2436/4885ALDH1A1 3722/4885
US-20170190680-A1 CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS KDM1B, PHF2, KDM6B KDM4E 14/4885HSD17B10 875/4885ALDH1A1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.